These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 23789839)

  • 21. Immunology and Immunotherapy of Head and Neck Cancer.
    Ferris RL
    J Clin Oncol; 2015 Oct; 33(29):3293-304. PubMed ID: 26351330
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adoptive cell transfer after chemotherapy enhances survival in patients with resectable HNSCC.
    Jiang P; Zhang Y; J Archibald S; Wang H
    Int Immunopharmacol; 2015 Sep; 28(1):208-14. PubMed ID: 26066298
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunotherapy of head and neck cancer.
    Resser JR; Carbone DP
    Curr Opin Oncol; 1998 May; 10(3):226-32. PubMed ID: 9619359
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of cytokines in the adoptive immunotherapy of an experimental model of human head and neck cancer by human IL-2-activated natural killer cells.
    Rabinowich H; Vitolo D; Altarac S; Herberman RB; Whiteside TL
    J Immunol; 1992 Jul; 149(1):340-9. PubMed ID: 1535088
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BCG immune activation reduces growth and angiogenesis in an in vitro model of head and neck squamous cell carcinoma.
    Sánchez-Rodríguez C; Cruces KP; Riestra Ayora J; Martín-Sanz E; Sanz-Fernández R
    Vaccine; 2017 Nov; 35(47):6395-6403. PubMed ID: 29029943
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunology of head and neck cancers.
    Newbill ET; Johns ME
    Crit Rev Clin Lab Sci; 1983; 19(1):1-25. PubMed ID: 6201320
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low levels of circulating invariant natural killer T cells predict poor clinical outcome in patients with head and neck squamous cell carcinoma.
    Molling JW; Langius JA; Langendijk JA; Leemans CR; Bontkes HJ; van der Vliet HJ; von Blomberg BM; Scheper RJ; van den Eertwegh AJ
    J Clin Oncol; 2007 Mar; 25(7):862-8. PubMed ID: 17327607
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Up-regulation of NK cell function against head and neck cancer in response to ss-isRNA requires TLR7.
    Pries R; Wulff S; Kesselring R; Börngen K; Xie L; Wollenberg B
    Int J Oncol; 2008 Nov; 33(5):993-1000. PubMed ID: 18949362
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The head and neck cancer immune landscape and its immunotherapeutic implications.
    Mandal R; Şenbabaoğlu Y; Desrichard A; Havel JJ; Dalin MG; Riaz N; Lee KW; Ganly I; Hakimi AA; Chan TA; Morris LG
    JCI Insight; 2016 Oct; 1(17):e89829. PubMed ID: 27777979
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The immune system and head and neck squamous cell carcinoma: from carcinogenesis to new therapeutic opportunities.
    Freiser ME; Serafini P; Weed DT
    Immunol Res; 2013 Dec; 57(1-3):52-69. PubMed ID: 24218361
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunotherapy for head and neck cancer: advances and deficiencies.
    De Costa AM; Young MR
    Anticancer Drugs; 2011 Aug; 22(7):674-81. PubMed ID: 21037467
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Functional alteration of myeloid dendritic cells through head and neck cancer.
    Brocks CP; Pries R; Frenzel H; Ernst M; Schlenke P; Wollenberg B
    Anticancer Res; 2007; 27(2):817-24. PubMed ID: 17465207
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Thymostimulin enhancement of T-cell infiltration into head and neck squamous cell carcinoma.
    Kerrebijn JD; Simons PJ; Balm AJ; Tas M; Knegt PP; de Vries N; Tan IB; Drexhage HA
    Head Neck; 1996; 18(4):335-42. PubMed ID: 8780944
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biology and immunology of cancer stem(-like) cells in head and neck cancer.
    Qian X; Ma C; Nie X; Lu J; Lenarz M; Kaufmann AM; Albers AE
    Crit Rev Oncol Hematol; 2015 Sep; 95(3):337-45. PubMed ID: 25907739
    [TBL] [Abstract][Full Text] [Related]  

  • 35. OX40 signaling in head and neck squamous cell carcinoma: Overcoming immunosuppression in the tumor microenvironment.
    Bell RB; Leidner RS; Crittenden MR; Curti BD; Feng Z; Montler R; Gough MJ; Fox BA; Weinberg AD; Urba WJ
    Oral Oncol; 2016 Jan; 52():1-10. PubMed ID: 26614363
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin 2 in patients with advanced squamous cell carcinoma of the head and neck.
    Whiteside TL; Letessier E; Hirabayashi H; Vitolo D; Bryant J; Barnes L; Snyderman C; Johnson JT; Myers E; Herberman RB
    Cancer Res; 1993 Dec; 53(23):5654-62. PubMed ID: 8242620
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of Immunotherapy in Head and Neck Cancer.
    Ling DC; Bakkenist CJ; Ferris RL; Clump DA
    Semin Radiat Oncol; 2018 Jan; 28(1):12-16. PubMed ID: 29173750
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regulatory T cells: what role do they play in antitumor immunity in patients with head and neck cancer?
    Alhamarneh O; Amarnath SM; Stafford ND; Greenman J
    Head Neck; 2008 Feb; 30(2):251-61. PubMed ID: 18172882
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dendritic cells pulsed with GST-EGFR fusion protein: effect in antitumor immunity against head and neck squamous cell carcinoma.
    Yang BB; Jiang H; Chen J; Zhang X; Ye JJ; Cao J
    Head Neck; 2010 May; 32(5):626-35. PubMed ID: 19787789
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel Treatment Options in Head and Neck Cancer.
    Schuler PJ; Laban S; Doescher J; Bullinger L; Hoffmann TK
    Oncol Res Treat; 2017; 40(6):342-346. PubMed ID: 28521322
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.